Back to 
Jacobs Levy Equity Management, Inc.
Jacobs Levy Equity Management, Inc.
AMLX
Showing 4 of 5 quarters
Position history for Jacobs Levy Equity Management, Inc.'s holdings in Amylyx Pharmaceuticals, Inc.
No. Jacobs Levy Equity Management exited its AMLX (Amylyx Pharmaceuticals) position in Q2 2025. Its Q1 2025 13F listed 77,091 shares worth $272,902. Jacobs Levy Equity Management first reported AMLX in Q2 2024 and held it in 4 quarterly 13F filings.
Final Value
$0
Final Shares
0
Total Value Change
-$1.6M
Total Shares Change
-478,440
Quarter-by-Quarter History
Other major holders of AMLX: FMR LLC, Viking Global Investors LP